0001104659-24-003741.txt : 20240112 0001104659-24-003741.hdr.sgml : 20240112 20240112170024 ACCESSION NUMBER: 0001104659-24-003741 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240110 FILED AS OF DATE: 20240112 DATE AS OF CHANGE: 20240112 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Martin Tami Tillotson CENTRAL INDEX KEY: 0001539494 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 24532679 MAIL ADDRESS: STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC. STREET 2: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 4 1 tm243247-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-01-10 0 0001356576 SUPERNUS PHARMACEUTICALS, INC. SUPN 0001539494 Martin Tami Tillotson C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE ROCKVILLE MD 20850 0 1 0 0 Sr. V.P., Regulatory Affairs 1 Common Stock 2024-01-10 4 M 0 8000 9.24 A 93664 D Common Stock 2024-01-10 4 S 0 8000 27.91 D 85664 D Employee Stock Option (Right to Buy) 9.24 2024-01-10 4 M 0 8000 0 D 2024-01-21 Common Stock 8000 0 D The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. Includes an aggregate of 415 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.69 to $28.22, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The option vested in four equal annual installments beginning on January 21, 2015. /s/ Timothy C. Dec, as attorney-in-fact 2024-01-12